Secreted Factors Determine Resistance To Idelalisib In Splenic Marginal Zone Lymphoma (Mzl) Models

ANNALS OF ONCOLOGY(2021)

Cited 0|Views4
No score
Abstract
PI3Kδ has a central role in the BCR signaling in hematological malignancies. Idelalisib was the first-in-class PI3Kδ inhibitor, and several novel compounds are undergoing clinical investigation. To identify modalities to overcome the resistance developed to these agents, we have developed idelalisib-resistant models derived from MZL cell lines.
More
Translated text
Key words
splenic marginal zone lymphoma
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined